Infect Chemother.  2009 Aug;41(4):224-229. 10.3947/ic.2009.41.4.224.

Evaluation of the Effect of Initial dose of Vancomycin using Serum Cystatin C as a Marker in Elderly Patients

Affiliations
  • 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. imfell@yuhs.ac
  • 2Therapeutic Drug Monitoring Team, Gangnam Severance Hospital, Seoul, Korea.

Abstract

BACKGROUND
It has been suggested that the glomerular filtration rate can be predicted on the basis of serum cystatin C concentration. The aim of this study was to investigate the clinical utility of serum cystatin C as a marker of renal function and to evaluate the effect of an initial dose of vancomycin using serum cystatin C concentration in elderly patients. MATERIALS AND METHODS: Data was collected from July 2006 to September 2008. The subjects were elderly patients (> or =60-years-of-age; n=number of patients) who had been treated with vancomycin. Serum concentrations of parameters including vancomycin, creatinine, and cystatin C were measured. Correlations between measured vancomycin concentrations and predicted vancomycin concentrations based on serum cystatin C or serum creatinine were compared, and the initial dose setting of vancomycin on the basis of serum cystatin C concentration was evaluated. RESULTS: Serum cystatin C was a good marker of renal function in comparison with serum creatinine for various doses of vancomycin in the elderly subject. In subpopulation (n=88) with normal serum cystatin C level (< or =1.2 mg/L) who were treated with routine adult vancomycin dose (1g q 12 hours), vancomycin concentration was within the therapeutic range (5-15 mg/L) in 68 patients (77.3%), and was <20 mg/L in 77 of the 88 patients (88.5 %). CONCLUSIONS: Predictive prowess of serum vancomycin concentrations on the basis of the serum cystatin C concentration could be better than that based on the serum creatinine concentration in elderly patients.

Keyword

Vancomycin; Therapeutic drug monitoring; Cystatin C

MeSH Terms

Adult
Aged
Creatinine
Cystatin C
Drug Monitoring
Glomerular Filtration Rate
Humans
Vancomycin
Creatinine
Cystatin C
Vancomycin

Figure

  • Figure 1 Correlations between measured and predicted vancomycin concentration on the basis of serum creatinine (A) and serum cystatin C (B).

  • Figure 2 Distribution of serum cystatin C concentration at normal range of serum creatinine concentration (≤1.0 mg/dL).

  • Figure 3 Distribution of serum creatinine concentration at normal range of serum cystatin C concentration (≤1.2 mg/L).


Cited by  2 articles

A Meta-Analysis on the Performance of Cystatin C- versus Creatinine-based eGFR Equations in Predicting Vancomycin Clearance
Nor Asyikin Mohd Tahir, Shamin Mohd Saffian, Farida Hanim Islahudin, Abdul Halim Abdul Gafor, Mohd Makmor-Bakry
J Korean Med Sci. 2020;35(37):e306.    doi: 10.3346/jkms.2020.35.e306.

Underestimation of the Calculated Area Under the Concentration-Time Curve Based on Serum Creatinine for Vancomycin Dosing
Sung Joon Jin, Ji Hyun Yoon, Bo Sook Ahn, Ji Ah Chung, Young Goo Song
Infect Chemother. 2014;46(1):21-29.    doi: 10.3947/ic.2014.46.1.21.


Reference

1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976. 16:31–41.
Article
2. Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant. 2005. 20:707–711.
Article
3. Verhave JC, Fesler P, Ribstein J, du Cailar G, Mimran A. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis. 2005. 46:233–241.
Article
4. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990. 25:679–687.
Article
5. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990. 25:679–687.
Article
6. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem. 2005. 38:1–8.
Article
7. Okamoto G, Sakamoto T, Kimura M, Ukishima Y, Sonoda A, Mori N, Kato Y, Maeda T, Kagawa Y. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem. 2007. 40:485–490.
Article
8. Christensson A, Ekberg J, Grubb A, Ekberg H, Lindström V, Lilja H. Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation. Nephron Physiol. 2003. 94:19–27.
Article
9. Pöge U, Gerhardt T, Stoffel-Wagner B, Klehr HU, Sauerbruch T, Woitas RP. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant. 2006. 21:660–664.
Article
10. Elliott TS, Foweraker J, Gould FK, Perry JD, Sandoe JA. Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2004. 54:971–981.
Article
11. American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005. 171:388–416.
12. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004. 39:1267–1284.
Article
13. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001. 45:2460–2467.
Article
14. Tanaka A, Suemaru K, Otsuka T, Ido K, Nishimiya T, Sakai I, Hasegawa H, Inoue T, Murase M, Yasukawa M, Araki H. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther Drug Monit. 2007. 29:261–264.
Article
15. Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit. 2006. 28:326–331.
Article
16. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000. 36:29–34.
Article
17. Choi NW, Kim JH, Lee CS, Lee CH, Kim GH, Kang CM. Relationship between serum cystatin C and glomerular filtration rate in renal transplant patients. Korean J Med. 2006. 70:672–680.
18. Han KH, Han SY, Kang YS, Cha DR. Serum cystatin C concentration compared with serum creatinine concentration as a marker of glomerular filtration rate. Korean J Nephrol. 2006. 25:737–744.
19. Kollef MH. Limitations of vancomycin in the management of resistant Staphylococcal infections. Clin Infect Dis. 2007. 45:Suppl 3. S191–S195.
Article
20. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005. 41:1159–1166.
Article
Full Text Links
  • IC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr